0A88 Stock Chart & Stats
$61.55
$0.95(2.07%)
At close: 4:00 PM EDT
$61.55
$0.95(2.07%)
Day’s Range― - ―
52-Week Range$11.17 - $79.89
Previous CloseN/A
Volume11.00
Average Volume (3M)3.39K
Market Cap
$10.03B
Enterprise Value$4.51K
Total Cash (Recent Filing)$552.03M
Total Debt (Recent Filing)$78.80M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 04, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding120,212,296
10 Day Avg. Volume3,382
30 Day Avg. Volume3,386
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.56
Price to Sales (P/S)3.17
P/FCF Ratio15.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$53.23Price Target Upside-13.52% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.74
Revenue Forecast (FY)$620.59M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables GrowthGrowing consumables usage supports the company’s recurring-revenue model after instruments are installed. Momentum in both single-cell reaction volumes and spatial workflows indicates deeper customer utilization, which can improve revenue durability and platform economics over the next several quarters.
Atera Commercial TractionEarly Atera demand demonstrates strong customer interest in a new spatial whole-transcriptome platform with single-cell sensitivity. If converted into installations and recurring assays, this traction could expand the installed base and create higher future consumables pull-through.
Liquidity And Cash GenerationStrong liquidity and positive operating and free cash flow provide financial flexibility while the company continues investing in product development and commercialization. Low leverage further reduces funding pressure and supports the ability to pursue growth without relying heavily on debt.
Bears Say
Revenue And Profitability WeaknessThe company has not yet established consistent top-line growth or sustained profitability. Continued net losses can constrain internal reinvestment and make operating performance more dependent on future adoption, cost discipline, and successful execution across its product portfolio.
Instrument Revenue DeclineThe sharp instrument decline signals weaker near-term capital-equipment demand and exposes the business to transition risk as customers moderate purchases of existing spatial products. Lower placements can also delay expansion of the installed base that drives future recurring consumables revenue.
Atera Shipment Capacity LimitsDemand is not translating fully into near-term revenue because shipment capacity limits the number of Atera systems delivered. Delayed installations defer instrument revenue and the associated consumables base, while concentrating execution and commercialization risk into the second half.
0A88 FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest share price was $11.17 and its highest was $79.89 in the past 12 months.
What is 10x Genomics Inc’s market cap?
10x Genomics Inc’s market cap is $10.03B.
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Nov 04, 2026 which is in 46 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.243 by $0.103.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Overvalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -0.26.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 120,212,296 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.243. Following the earnings report the stock price went up 10.77%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Currently, no hedge funds are holding shares in GB:0A88
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
10x Genomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$53.23 (-13.52% Downside)
$53.23 (-13.52% Downside)
Blogger Sentiment
Neutral
GB:0A88 Sentiment 71%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $5.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
477.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
10x Genomics Inc
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
0A88 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a constructive mix of operational positives — notably Atera's outsized early demand, solid consumables growth (+7% total; spatial +16%), gross margin expansion to 74%, and a raised full‑year revenue guide — while flagging near‑term cadence challenges driven by instrument revenue declines (‑47%) and manufacturing/shipment constraints for Atera that produce an expected Q3 sequential dip. The business shows healthy underlying consumable momentum and strategic positioning (M&A, multi‑omics, AI tailwinds), but short‑term instrument timing and APAC comparatives introduce visibility headwinds.View all GB:0A88 earnings summaries0A88 Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China

0A88 Stock 12 Month Forecast
Average Price Target
$53.23
▼(-13.52% Downside)
Technical Analysis
Omnicell
―
Schrodinger
―
GeneDx Holdings
―
SOPHiA GENETICS
―
Hinge Health, Inc. Class A
―











